Tesofensine

Research-centric overview

Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.

No effect profile data seeded yet for this peptide.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Jun 2, 2026

Studies indexed

Human

Animal

AI analyzed

Evidence mix0% human · 0% animal · 0% cellular · 0% review

Highest phase: Preclinical onlyYears covered: —

Librarian pulse — latest actionsFull changelog ↓

Jun 2, 6:00 AMRefreshedRefreshed content for Tesofensine
May 28, 6:02 AMRefreshedRefreshed content for Tesofensine
May 26, 2:25 PMtask_runCompleted task: Refresh content for Tesofensine

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Prader-Willi SyndromeClinical TrialClinicalTrials.govPublished Dec 28, 2021Added May 27, 2026

This study evaluated the safety and efficacy of Tesomet in subjects with Prader-Willi Syndrome over a 16-week period, followed by an open-label extension. The study involved a randomized, double-blind, placebo-controlled design. No therapeutic claims are made regarding the outcomes.

Phase: PHASE2Status: WITHDRAWN

A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent PatientsClinical TrialClinicalTrials.govPublished Mar 30, 2017Added May 27, 2026

This study evaluated the safety and efficacy of co-administration of Tesofensine and Metoprolol over 12 weeks in patients with Prader-Willi Syndrome (PWS). The study included both adult and adolescent patients. Results regarding specific outcomes were not reported in the abstract.

Phase: PHASE2Status: COMPLETED

A Phase 1 Study to Examine Pharmacodynamic Interaction Between Tesofensine and Metoprolol on 24-hours Mean Heart RateClinical TrialClinicalTrials.govPublished Jul 11, 2018Added May 27, 2026

This study examined the pharmacodynamic interaction between Tesofensine and Metoprolol on 24-hour mean heart rate. The population and specific dosing information were not detailed in the abstract. The findings regarding heart rate changes were not reported in the abstract.

Phase: PHASE1Status: COMPLETED

A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)Clinical TrialClinicalTrials.govPublished Apr 1, 2016Added Apr 16, 2026

This study evaluated the safety and efficacy of co-administration of Tesofensine and Metoprolol in subjects with Type 2 Diabetes Mellitus (T2DM). The specific doses and outcomes were not detailed in the abstract. The study aimed to determine the effects of this combination treatment on patients with T2DM.

Phase: PHASE2Status: COMPLETED

A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 WeeksClinical TrialClinicalTrials.govPublished Feb 25, 2019Added Apr 16, 2026

This study evaluated the safety and tolerability of co-administration of Tesofensine and Metoprolol in subjects with hypothalamic injury-induced obesity over 48 weeks. The study included a 24-week double-blind randomized placebo-controlled phase followed by a 24-week open-label extension. No therapeutic claims are made regarding the outcomes.

Phase: PHASE2Status: COMPLETED

A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)Clinical TrialClinicalTrials.govPublished Jun 1, 2003Added Apr 16, 2026

This study evaluated the efficacy and safety of NS 2330 in early Parkinson's disease patients over a fourteen-week period. The study involved a placebo-controlled, dose-response design. No therapeutic claims are made regarding the outcomes.

Phase: PHASE2Status: COMPLETED

The Effect of Tesofensine on Energy Balance in Humans. A Randomised, Double-Blind, Placebo-Controlled, Parallel- Group, Single Centre Study.Clinical TrialClinicalTrials.govPublished Mar 1, 2007Added Apr 16, 2026

This study evaluated the effect of Tesofensine on energy balance in humans through a randomized, double-blind, placebo-controlled design. The specific population, dose, and outcomes were not detailed in the abstract. The findings regarding energy balance were not reported in the abstract.

Phase: PHASE1, PHASE2Status: COMPLETED

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)Clinical TrialClinicalTrials.govPublished Mar 1, 2003Added Apr 16, 2026

This study evaluated the efficacy and safety of NS 2330 (tesofensine) at doses of 0.125 mg, 0.25 mg, 0.5 mg, and 1.0 mg administered orally once daily over 14 weeks in levodopa-treated Parkinson's disease patients experiencing motor fluctuations. The study aimed to explore the potential of NS 2330 as a treatment option. No therapeutic claims are made.

Phase: PHASE2Status: COMPLETED

Semantic Scholar search for TesofensineStudySemanticScholarAdded Dec 12, 2025

Not reported in abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

11h agoRefreshai-researcher85%

Refreshed content for Tesofensine

5d agoRefreshai-researcher85%

Refreshed content for Tesofensine

May 26task_runlibrarian-runner

Completed task: Refresh content for Tesofensine

May 26Refreshdiscovery50%

Refreshed content for Tesofensine

May 26SummarySemanticScholar0%

Auto-summarized study: "Semantic Scholar search for Tesofensine..."